Ethinyl FIGURE 3. Triglyceride concentrations throughout the oral fat tolerance test before and 12 weeks after weight loss. 18-23 Lipsey JR. Robinson RG, Pearlson Cl ; , Rao K, Price TR: Nortriptylmmie treatment of post-stroke depression: a double-blind study. Lancet 1984; 1: 297-300 Reding MJ, Orto IA, Winter SW, Forttmna IM, Di Pomite PM, McDowell FH: Antidepressant therapy after stroke: a doubleblind trial. Arch Nurol 1986; 43: 763-765 Mayherg HS, Robinson RG, Wong DF, Panmkli R, Bolduc P. Comment on how long phenindamine tartrate has been used in pharmacy compounding and how widespread that use has been. Phenyltoloxamine Dihydrogen Citrate Phenyltoloxamine dihydrogen citrate, a structural isomer of diphenhydramine, is well-characterized chemically. used as an antihistamine. It has been. The prevalence of age-related changes in the vagina can vary with hormonal status, coexistent vascular disease, and the continuation or lack of sexual activity. [43] The postmenopausal decrease in oestrogen plays a part in many age-associated vaginal changes. Oestrogen is trophic for much of the LUT track in women, with oestrogen receptors found in the vagina, vestibule, distal urethra, bladder trigone, pelvic muscles, and ligamentum rotundum. [44] Yet, as the Women's Health Initiative[45] and HERS trial have shown, [46] one cannot assume that the association between low oestrogen levels and physiological changes implies that hormone replacement will reverse these changes, restore function, or reduce symptoms. Moreover, the data are equivocal on whether and how LUT oestrogen receptors decrease in number, density, or function in older women. [31] Following menopause, the vaginal epithelium loses the majority of its superficial and intermediate layers. Mucosal thinning may be associated with inflammation, evident as erythema, telangiectasias, petechiae, friability, and erosions. This may be responsible for irritative LUTS in many frail elderly women. In addition, there is loss of epithelial glycogen and lubrication, and mucosal pH increases from 4.5-5.5 to 7.0-7.4. [31] These changes can lead to loss of normal adherent flora lactobacillus ; , and colonization with pathogenic organisms such as E coli and enterococci. This in turn may result in recurrent symptomatic urinary tract infections and some associated LUTS. Vaginal blood flow, which is important for mucosal integrity and submucosal fullness, decreases with age. Whether this is oestrogen-related, and or due to concomitant vascular disease is not known. Collagen. Conclusion TRAFFIC is a promising start for a new therapeutic approach to the difficult problem of intermittent claudication. Unfortunately, it is not the "slam-dunk" success that portends the end of physical disability in patients with intermittent claudication. As we await phase 2 and 3 trials using other growth factors, other methods of delivery, and possibly growth factor combinations, physicians will still have to rely on current methods for palliation of symptoms. Supervised exercise therapy should remain the mainstay of therapy. Patients without left ventricular dysfunction can be treated with cilostazol. These two therapies provide a demonstrable benefit to walking distance that is greater than what the current angiogenesis trials seem to promise Figure 1 ; . Adjunctive growth factor therapy may further improve walking distance. The mechanism of action for rFGF-2 remains unclear. It is interesting that there is no dose effect, that the results are adversely affected by smoking, and that benefit seen at 90 days did not persist. There was a slight increase in the ankle-brachial index with therapy. Improvements in perfusion pressure may be more important for wound healing than walking distance and may imply a future direction for growth factor therapy. Patients with intermittent claudication must live with a disability that decreases their quality of life and leaves them at increased risk for limb loss. The severity of their impairment creates a clinical imperative to search for new therapies to forestall the need for revascularization. Such clinical imperatives will drive investigators to conduct more studies to understand the mechanism that causes growth factors to confer their benefit and determine the appropriate clinical settings where they can improve the lives of patients with peripheral arterial disease. Cardiac Catheterization Significantly revised LCD-Effective for services on or after 09 23 2006 ; Category III CPT Codes Significantly revised LCD-Effective for services on or after 09 23 2006 ; Multislice or Multidetector Computed Tomographic Angiography of the Heart and Great Vessels Significantly revised LCD-Effective for services on or after 09 23 2006 ; Please access the complete LCD via: : medicarenhic ne prov policies.shtml and click on the appropriate link under Active Local Coverage Index ; Pending LCDs The following Draft LCD was presented at the October 30, 2006, Contractor Advisory Committee Meeting CAC ; , and is pending finalization. Balloon Sinuplasty Please access the complete LCD via: : medicarenhic ne prov policies.shtml and click on the appropriate link under Draft Local Coverage Determination Index ; Paper Copies and E-Mailing List You may subscribe to the LCD mailing list for NHIC by going to : medicarenhic , clicking on `Part B Mailing List' completing the form making sure to request General NHIC Website Updates or New England Policies in order to receive weekly electronic Medicare B updates. To obtain a hard copy of any of the LCDs for NHIC you may contact Customer Service at the phone numbers identified on the inside back cover or by writing to Customer Service at: ME, MA, NH, VT : Written Correspondence Medicare PO Box 1000 Hingham, MA 02044 and estradiol. Segal K, Van Loan M, Fitzgerald P, Hodgdon J, Van Itallie T. 1988 Lean body mass estimation by bioelectrical impedance analysis: a four-site cross-validation study. J Clin Nutr. 47: 7-14. Lukaski H, Bolonchuk W, Hall C, Siders W. 1986 Validation of tetrapolar bioelectrical impedance method to assess human body composition. J Appl Physiol. 60: 1327-1332. McCulloch D, Bingley P, Colman P, Jackson R, Gale E. 1993 Comparison of bolus and infusion protocols for determining acute insulin response to intravenous glucose in normal humans. Diabetes Care. 16: 911-915. Allain C, Poon L, Chan C, Richmond W, Fu P. 1974 Enzymic determination for total serum cholesterol. Clin Chem. 20: 470-475. Bucolo G, David H. 1978 Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem. 19: 476-482. Friedewald W, Levy R, Frederickson D. 1972 Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin Chem. 18: 499503. Gidez L, George J, Burstein M, Eder H. 1979 Analysis of plasma high density lipoprotein subclasses by a precipitation procedure: correlation with preparative and analytical ultracentrifugation. Report of the high density lipoprotein methodology workshop. U.S. Department of Health, Education and Welfare, National Institutes of Health. 328. Geffner M, Kaplan S, Bersch N, Golde D, Landaw E, Chang RJ. 1986 Persistence of insulin resistance in polycystic ovarian disease after inhibition of ovarian steroid secretion. Fertil Steril. 45: 327-333. Pasquali R, Venturoli S, Paradis R, Capelli M, Parenti M, Melchionda N. 1982 Insulin and C-peptide levels in obese patients with polycystic ovaries. Horm Metab Res. 14: 284-287. Holte J, Bergh T, Beme C, Berglund L, Lithe11 H. 1994 Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance. J Clin Endocrinol Metab. 78: 1052-1058. Ovesen P, Moller J, Ingerslev H, et al. 1993 Normal basal and insulin-stimulated fuel metabolism in lean women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 77163661639. Wild RA, Grubb B, Hartz A, Van Nort JJ, Bachman W, Bartholomew M. 1990 Clinical signs of androgen excess as risk factors for coronary artery disease. Fertil Steril. 54: 255-259. Ehrmann D, Rosenfield R. 1990 An endocrinological approach to the patient with hirsutism. J Clin Endocrinol Metab. 71: 1-4. O'Brien R. Coouer M. Murrav R, Seeman E, Thoma A, lerums G 1991 Comparison of sequentiai cyproterone acetate estrogen versus spironolactone oral contraceptive in the treatment of hirsutism. J Clin Endocrinol Metab. 72: 1008-1013. Cole C, Kitabchi A. 1978 Remission of insulin resistance IR ; with Orthonovum in a patient with polycystic ovarian disease and acanthosis nigricans #`COD-AN ; . Clin Res. 26: 412A Abstract ; . Pasquali R, Fabbri R, Venturoli S, Paradisi R, Antenucci D, Melchionda N. 1986 Effect of weight loss and antiandrogenic therapy on sex hormone blood levels and insulin resistance in obese patients with polycystic ovaries. J Obstet Gynecol. 154: 139-143. Skouby S, Anderson 0, Saurbrey N, Kuhl C. 1987 Oral contraception and insulin sensitivity: in viva assessment in normal women and women with previous gestational diabetes. J Clin Endocrinol Metab. 64: 519-523. Kasdorf G, Kalkhoff R. 1988 Prospective studies of insulin sensitivity in normal women receiving oral contraceptive agents. J Clin Endocrinol Metab. 66: 846-852. Spellacy W. 1982 Carbohydrate metabolism during treatment with estrogen, progestogen, and low-dose oral contraceptives. J Obstet Gynecol. 142: 732-734. Kojima T, Lindheim S, Duffy D, Vijod M, Stanczyk F, Lobo R. 1993 Insulin sensitivity is decreased in normal women by doses of ethinyl estradiol used in oral contraceptives. J Obstet Gynecol. 169: 1540-1544. Spellacy W, Birk S, Buggie J, Buhi W. 1981 Prospective carbohydrate metabolism studies in women using a low-estrogen oral contraceptive for one year. J Reprod Med. 26: 295-298. Lobo RA. 1988 The androgenicity of progestational agents. Int J Fertil. 6-12. DeFronzo R. 1992 Insulin resistance, hyperinsulinemia, and coro! Davies DF, Shock NW. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest. 1950; 29: 496-507. Luke DR, Halstenson CE, Opsahl JA, Matzke GR. Validity of creatinine clearance estimates in the assessment of renal function. Clin Pharmacol Ther. 1990; 48: 503-508. Muhlberg W, Platt D. Age-dependent changes of the kidneys: pharmacological implications. Gerontology. 1999; 45: 243-253. Shimomura K, Kamata O, Ueki S, Ida S, Oguri K. Analgesic effect of morphine glucuronides. Tohoku J Exp Med. 1971; 105: 4552. Osborne RJ, Joel SP, Selvin ml. Morphine intoxication in renal failure: the role of morphine-6-glucuronide. Br Med J Clin Res Ed ; . 1986; 292: 1548-1549. Sawe J, Svensson JO, Odar-Cederlof I. Kinetics of morphine in patients with renal failure [letter]. Lancet. 1985; 2: 211. Hylek EM. Oral anticoagulants: pharmacologic issues for use in the elderly. Clin Geriatr Med. 2001; 17: 1-13. Swift CG, Ewen JM, Clarke P, Stevenson IH. Responsiveness to oral diazepam in the elderly: relationship to total and free plasma concentrations. Br J Clin Pharmacol. 1985; 20: 111-118. Castleden CM, George CF, Marcer D, Hallett C. Increased sensitivity to nitrazepam in old age. BMJ. 1977; 1: 10-12. Cusack BJ, Nielson CP, Vestal RE. Geriatric clinical pharmacology and therapeutics. In: Speight TM, Holford NHG, eds. Avery's Drug treatment. 4th ed. Auckland, New Zealand: Adis International; 1997: 173-223 and norethindrone. 25. Sulak PJ, Carl J, Gopalakrishnan I, et al. Outcomes of extended oral contraceptive regimens with a shortened hormone-free interval to manage breakthrough bleeding. Contraception. In press. 26. Stancyk FZ, Roy S. Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids. Contraception. 1990; 42: 67-96. Stancyzk FZ. Pharmacokinetics of the new progestins and influence of gestodene and desogestrel on ethinyl estradiol metabolism. Contraception. 1997; 55: 273-282. Fotherby K. Pharmacokinetics and metabolism of progestins in humans. In: Goldzieher JW, Fotherby K, eds. Pharmacology of the Contraceptive Steroids. New York, NY: Raven Press; 1994: 99-126. 29. Petitti DB. Combination estrogen-progestin oral contraceptives. N Engl J Med. 2003; 349: 1443-1450. Speroff L, Darney PD. Oral contraception. In: A Clinical Guide for Contraception. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001: 121-137. 31. Gaspard U, Scheen A, Endrikat J, et al. A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism. Contraception. 2003; 67: 423-429. Oelkers W, Foidart JM, Dombrovicz N, et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab. 1995; 80: 1816-1821. Foidart JM, Wuttke W, Bouw GM, et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care. 2000; 5: 124-134. Brown C, Ling F, Wan J. A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms. J Reprod Med. 2002; 47: 14-22. Ortho Tri-Cyclen norgestimate ethinyl estradiol ; [prescribing information]. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc.; rev 2001. 36. Estrostep norethindrone acetate ethinyl estradiol tablets ; . Physicians' Desk Reference, 57th ed. Montvale, NJ: Thomson PDR; 2003: 2535-2544. 37. Fugere P, Percival-Smith RK, Lussier-Cacan S, et al. Cyproterone acetate ethinyl estradiol in the treatment of acne. A comparative dose-response study of the estrogen component. Contraception. 1990; 42: 225-234. van Vloten WA, van Haselen CW, van Zuuren E, et al. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis. 2002; 69: 2-15. Thorneycroft IH, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis. In press. Introduction It has been hypothesized that the accumulation of several mutations plays an important role in carcinogenesis. For breast carcinoma, it has been estimated that nine mutations are required after birth 1 ; . However, neither the mutation rate reported for normal human cells nor the increased mitotic activity in malignant cells can account for this rapid accumulation of mutations 2 ; . Therefore, it has been suggested that neoplastic cells have acquired the capacity to accelerate the and cabergoline. Differences in plasma catecholamines in response to H exercise, other mechanisms may be at play during H to increase lactate levels during, and decrease glucose uptake after, exercise in men vs. women. One factor is the greater absolute work rates for the men 87.1 2.9, 130.7 and 174.2 5.8 W vs. 64.2 2.3, 96.4 and 128.5 4.6 W for E1, E2, and E3, respectively, in men vs. women; gender time interaction; P 0.0001 ; . Greater workloads suggest greater energy turnover and more glycolytic flux, leading to greater lactate levels. The signals that stimulate the activation of glycogen phosphorylase to increase glycogenolysis could be inorganic phosphate and calcium, which result directly from muscle contraction. Another factor is estrogen. Administration of estrogen to rats has been shown to spare glycogen during exercise, possibly by increasing lipid availability during exercise 18 ; . However, the route by which estrogen increases lipid availability is unknown. Regardless of the mechanism s ; , if women were using less glycogen during hypoxia, they would produce less lactate during exercise. After exercise, the need for glycogen repletion would be less and might contribute to reduced removal and consequently increased plasma levels of glucose. These factors could explain why differences in metabolic responses to hypoxic exercise occurred in the absence of a blunted endocrine response to hypoxic exercise. Based on the finding that lactate levels were quite variable for a given exercise intensity relative to VO2 max, it has been suggested that exercise intensity should be expressed relative to the lactate threshold rather than as a percentage of VO2 max 27 ; . However, the results showed no impact of gender on the lactate threshold expressed as %VO2 max or power output per kilogram fat-free mass 2.7 0.19 vs. 2.7 0.23% VO2 max in men vs. women; P 0.05 ; . Despite some variability ranges from 87.3 to 137.1% lactate threshold vs. 73.8 to 137.1% lactate threshold at E3 in men vs. women ; , there was no impact of gender on the exercise intensity for E1, E2, and E3 as expressed relative to the lactate threshold in men vs. women 48.6 3.6, 72.9 lactate threshold vs. 49.0 3.9, 73.5 lactate threshold in men vs. women for E1, E2, and E3, respectively; P 0.05 ; . In addition, the men and women were consuming the same amount of oxygen per kilogram fat-free mass, reflecting very similar relative exercise intensities. Thus the gender differences in this study were most likely not due to the fact that exercise intensity was expressed relative to VO2 peak. The female subjects in this study were all taking OC so that we could avoid the complications of studying women during the menstrual cycle. Because of the difficulty in recruiting subjects, the brand or length of time taking OC was assessed but not controlled. All OC prescriptions used by the subjects in this study contained ethinyl estradiol as the synthetic estrogen, albeit at different dosages in some cases. Estrogen and progestin dosage within each OC may have an independent impact on hormonal and metabolic response to exercise. However, there were no correlations between. The only progestin available in an oral contraceptive OC ; formulation that exhibits antiandrogen activity is drosperinone found in a formulation that also contains 20 mcg of ethinyl estradiol YAZ ; . This formulation is approved for moderate acne and is comprised of 24 days of active therapy and 4 hormonefree days, resulting in a short menstrual cycle. In a placebocontrolled, randomized, double-blind, 6-cycle clinical study, 451 females received the active OC formulation and 442 received placebo. After the first cycle, subjects receiving active OC treatment demonstrated a markedly greater reduction in total acne lesions, which continued to progress throughout the sixth cycle study endpoint and progesterone! Of the parent levonorgestrel also circulates as 17-sulfate. Metabolic clearance rates may differ among individuals by several fold, and this may account in part for the high variability observed in levonorgestrel concentrations among users. Ehhinyl Estradiol: The cytochrome P450 enzyme CYP3A4 ; is responsible for the 2hydroxylation that is the major oxidative reaction. The 2-hydroxy metabolite is further transformed by methylation and glucuronidation prior to urinary and fecal excretion. Levels of Cytochrome P450 CYP3A ; vary widely among individuals and can explain the variation in rates of ethinyl estradiol 2-hydroxylation. Ethiyl estradiol is excreted in the urine and faeces as glucoronides and sulfates and undergoes enterohepatic circulation. Excretion The elimination half-life for levonorgestrel after a single dose of two ECPs is 40.8 19 hours. Levonorgestrel and its metabolites are primarily excreted in the urine. The elimination half-life of ethinyl estradiol is 21.2 9.3 hours. Special Populations This product is not intended for use in geriatric age 65 or older ; or pediatric premenarchal ; populations and pharmacokinetic data are unavailable for these populations. Steroid hormones may be poorly metabolized in patients with impaired liver function see Precautions-Liver Function ; Race, Hepatic Insuffiency, and Renal insuffiency: No formal studies have evaluated the effect of race, hepatic disease and renal disease on the disposition of the ECPs. Drug-Drug Interactions No specific drug-drug interaction studies for the ECPs were conducted but there are many publications that indicate that interactions between ethinyl estradiol and other drugs may occur. Other drugs may decrease the effectiveness of ethinyl estradiol or other drugs may enhance ethinyl estradiol levels resulting in possible increased side-effects. Ethinyp estradiol may interfere with the metabolism of other compounds. In general, the effect of other drugs on ethinyl estradiol is due to interference with the absorption, metabolism or excretion of ethinyl estradiol, whereas the effect of ethinyl estradiol on other drugs is due to competition for metabolic pathways. Absorption interactions: Infective diarrhea may induce failure of ethinyl estradiol by increasing gastrointestinal motility and reducing hormone absorption. Therefore, any drug which increases gastrointestinal transit and causes diarrhea is potentially likely to reduce concentrations of ethinyl estradiol. Interactions with metabolism: Gastrointestinal Wall: The gastrointestinal wall has been shown to be a site for interaction for the sulfation of ethinyl estradiol. Inhibition of the sulfation in the gastrointestinal tract may increase the bioavailability of ethinyl estradiol and result in possible increased side-effects. For example, ascorbic acid acts as competitive inhibitor for sulfation in the gastrointestinal wall increasing ethinyl estradiol bioavailability about 50. Address: 1Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, MS 39216, USA and 2Tougaloo College, Tougaloo, MS, USA Email: G Howell - ghowell pharmacology.umsmed ; L West - lashondrapowell yahoo ; C Jenkins - colibrinecole aol ; B Lineberry - Larry.Lineberry usma ; D Yokum - DVyokum bsc ; R Rockhold * - rrockhold pharmacology.umsmed * Corresponding author Equal contributors and clomiphene. A study comparing a traditional 28-day cycle with an extended 49-day cycle of a 30-mg ethinyl estradiol EE ; 300-mg norgestrel monophasic birth control regimen Lo Ovral 28 ; was conducted from April 1998 to April 2000.6 The objective was to compare the two regimens in terms of differences in bleeding patterns, symptoms, need for sanitary protection pads or tampons ; , and overall patient satisfaction. Patients were randomly assigned to either 21 7-day or 42 7-day cycles over four 84-day reference periods or trimesters. During this time, they kept diaries on bleeding, pill taking, and symptoms. Of the 90 women who began the study, 24 54.5 percent ; using the 28-day cycle and 29 63 percent ; using the 49-day cycle completed the study. The two groups were similar in demographics and continuation rates. Bleeding and Spotting. For the two treatment arms, there were no significant differences in amenorrhea, frequent menses more than four episodes of bleeding per trimester ; , or prolonged withdrawal bleeding. In the first trimester, the number of bleeding days was significantly reduced with the extended OC cycle: the mean number of bleeding days was 10.9 for the 21 7-day cycle and 6.4 for the 42 7-day cycle p 0.00 ; . The number of spotting days in the first trimester was similar between schedules mean number of spotting days 4.8 for the 28-day regimen and 3.7 for the 49-day regimen; p 0.24 spotting was reduced by the fourth trimester 3.4 days for the 28-day regimen and 2.9 days for the 49-day regimen; p 0.30 ; . Hygiene Product Use. Women using the extended regimen spent significantly less on hygiene products and needed them for significantly fewer days. Satisfaction. Women's satisfaction with their pill schedules was similar for the two regimens. Continued Contraceptive Use. At the study exit, 52.4 percent of women who had been assigned to the extended regimen wished to continue with it and 16.7 percent who had been assigned to the 28-day regimen wished to switch to the extended regimen. Correspondence: Professor Kesara Na-Bangchang, Pharmacology and Toxicology Unit, Graduate Program in Biomedical Sciences, Faculty of Allied Health Sciences, Thammasat University Rangsit Campus ; , Paholyothin Road, Pathumthani 12121, Thailand. Tel: 66 0 ; 2926-9438; Fax: 66 0 ; 2516-5379 E-mail: kesaratmu yahoo , nkesara tu.ac.th and anastrozole. Iting, intermenstrual bleeding, weight gain, and breast tenderness. The risks and drug interactions are considered to be the same as with any other hormonal contraceptive. Practical considerations. With any oral contraceptive, it is important to take the pill at the same time every day to ensure a steady level of hormones. Missing a pill for more than 24 hours increases the risk of pregnancy, and the patient should be instructed to take one pill as soon as she remembers, and the next pill at the regular time. If two pills are missed, two pills have to be taken on the day the patient remembers, two pills the next day, and one pill a day thereafter. SEASONIQUE: FOUR CYCLES PER YEAR Long-cycle hormonal contraceptives reduce the number of withdrawal menses periods from one per month to four per year. Seasonale ethinyl estradiol 30 g and levonorgestrel 0.15 mg ; is a long-cycle oral contraceptive that has been available since 2003: patients receive active treatment for 12 weeks followed by placebo for 1 week, which is the For women week for scheduled bleeding. Seasonique, which was approved in May with 2006, is the same formulation as Seasonale but hemochromawith the addition of ethinyl estradiol in a lower dose 10 g ; during the 13th week, tosis, regular without levonorgestrel. menstrual Effectiveness. In a 1-year, multicenter, bleeding may open-label study, 7 Seasonique was more than be a good thing 99% effective in preventing pregnancy when taken as directed, with a method failure rate Pearl index ; of 0.78. Cycle control and safety of the regimen were similar to those reported for other hormonal contraceptives. Advantages. Some women may choose long-cycle hormonal contraceptives for lifestyle and cosmetic reasons, ie, to have fewer periods. Symptoms related to hormone withdrawal, such as headache and dysmenorrhea, are reduced with this extended-cycle oral contraceptive, as the number of withdrawal bleeding periods are reduced to four per year as opposed to 13. The addition of low-dose ethinyl estradiol during the 13th week with Seasonique may reduce the hormonal withdrawal symptoms. Norethindrone ethinyl estrad 199 selected aspects of the pharmacokinetics and metabolism of ethinyl estrogens and their clinical application and letrozole. Claim 1 of the second auxiliary request differed from claim 1 of the first auxiliary request in that the daily amounts of estrogen and progestin were amended to be "equivalent to 5-35 mcg of ethinyl estradiol and 0.025 to 10 mg of norethindrone acetate, respectively. Ethinyl estradiol fertility Dividends Teva has paid dividends on a regular quarterly basis since 1986. Future dividend policy will be reviewed by the board of directors based upon conditions then existing, including Teva's earnings, financial condition, capital requirements and other factors. Teva's ability to pay cash dividends may be restricted by instruments governing its debt obligations. Dividends are declared and paid in New Israeli Shekels "NIS" ; . Dividends are converted into U.S. dollars and paid by the depositary of Teva's ADRs for the benefit of owners of ADRs, and are subject to exchange rate fluctuations between the NIS and the U.S. dollar between the declaration date and the date of actual payment. Dividends paid by an Israeli company to shareholders residing outside Israel are generally subject to withholding of Israeli income tax at a rate of up to 20%. Such tax rates apply unless a lower rate is provided in a treaty between Israel and the shareholder's country of residence. In Teva's case, the applicable withholding tax rate will depend on the particular Israeli production facilities that have generated the earnings that are the source of the specific dividend and, accordingly, the applicable rate may change from time to time. The rate of tax withheld on the dividend declared for the fourth quarter of 2006 was 16%. The following table sets forth the amounts of the dividends paid in respect of each period indicated prior to deductions for applicable Israeli withholding taxes in cents per share ; . All figures have been adjusted to reflect the 2-for-1 stock splits effected in June 2004 and December 2002 and capecitabine. Herceptin Trastuzumab ; On September 2, 1998, Herceptin was recommended for approval as a single agent treatment in patients who have received prior therapy and in combination with Taxol for patients who had not received prior therapy or advanced breast cancer cancer that has spread to other parts of the body ; . Ongoing discussions between the FDA Food and Drug Administration ; and the company who manufactures the drug Genentech ; will address the outcome of this issue. The panel's favorable vote is a significant step toward FDA approval and the FDA is expected to make a decision on Herceptin approval by November of 1998. However, the drug is still available for eligible patients through ongoing clinical trials until Herceptin is approved. 3 ; Like Rituxan it is a monoclonal antibody, designed to attack specific cancer cells. Herceptin binds specifically to the antigen HER2 neu. It is indicated for patients whose breast cancer is positive for the antigen HER2 neu, which occur in about 25 to 30% of breast cancers. Herceptin is administered as an intravenous infusion over 30 to 90 minutes once a week for as long as benefit is seen, and in the absence of. Print, broadcast, and Internet media play critical roles in reporting and educating, as well as influencing public opinion. Local and national media differ widely in their portrayals of opioid addiction, MAT, and people addicted to opioids. These differences reflect a combination of factors including journalistic integrity, reporting style and philosophy, political leanings, regional influences, and business considerations. News accounts and other depictions of MAT often seem limited, misinformed, and negative. Nevertheless, many noteworthy, responsible features have been produced, providing important, accurate information to the public about the science and policy of opioid addiction and treatment e.g., Barry 2002; Hammack 2002; Moyers and Moyers 1998 ; . Although treatment providers sometimes are disciplined to resist media exposure in order to protect patient confidentiality and avoid misrepresentation, the consensus panel believes that successful media outreach enhances an OTP's image, improves understanding of a program's mission and methods, and generates supportive public policies. Media outreach can demystify treatment, counteract stigma, and improve fairness of coverage. OTPs operating in larger institutions can work with institutional public affairs professionals. Administrators should respond to or address members of the local press when necessary, as and tegaserod and Ethinyl online. Side effects of levonorgestrel and ethinyl estradiol tablets BrandName Bacitracin Bacitracin Zinc Bacitracin Zinc Neomycin SO4 Polymyxin B Bacitracin, Ophthalmic Bacitracin, Topical Bacitracin HC Neomycin Polymyxin Bacitracin Neomycin Polymyxin B Ophthalmic Bacitracin-Neo-Poly Bacitracin-Polymyxin Bacitracin-Polymyxin, Ophthalmic Backache Relief Extra Strength Baclofen Baclofen Baclofen Bacmin Bactine Bactocill Bactocill Bactocill Bactocill Bactocill Bactocill Bactocill Bactramycin Bactrim Bactrim DS Bactrim I.V. Bactrim Pediatric Bactroban Bactroban Bactroban Bag Balm BAL In Oil Balacet Balanced B-100 Balanced B-100 High Potency Caplets Balanced B-100 Time Released High Potency Balanced B-150 Balanced B-50 Balanced Salt Solution Balanta Balmex Balneol Balnetar Balox Plus Balziva Banalg Banalg Hospital Strength DrugName bacitracin bacitracin topical bacitracin neomycin polymyxin B topical bacitracin ophthalmic bacitracin topical bacitracin HC neomycin polymyxin B ophthalmic bacitracin neomycin polymyxin B ophthalmic bacitracin neomycin polymyxin B topical bacitracin-polymyxin B topical bacitracin-polymyxin B ophthalmic magnesium salicylate baclofen baclofen baclofen multivitamin with minerals lidocaine topical oxacillin oxacillin oxacillin oxacillin oxacillin oxacillin oxacillin lincomycin sulfamethoxazole-trimethoprim sulfamethoxazole-trimethoprim sulfamethoxazole-trimethoprim sulfamethoxazole-trimethoprim mupirocin topical mupirocin topical mupirocin topical emollients, topical dimercaprol acetaminophen-propoxyphene multivitamin multivitamin multivitamin multivitamin multivitamin ophthalmic irrigation, intraocular Al hydroxide mg hydroxide simethicone zinc oxide topical emollients, topical coal tar topical Al hydroxide mg hydroxide simethicone ethinyl estradiol-norethindrone methyl salicylate topical methyl salicylate topical Strength 50000 units zinc 400 units-3.5 mg-5000 units g 500 units g 500 units g 400 units-10 mg-3.5 mg-10000 units g 400 units-3.5 mg-10000 units g 400 units-3.5 mg-5000 units g 500 units-10000 units g 500 units-10000 units g 467 mg 10 mg 20 mg Therapeutic Multiple Vitamins with Minerals 2.5% 1g 10 g 2g 250 mg 4g 500 mg 500 mg 300 mg ml 400 mg-80 mg 800 mg-160 mg 80 mg-16 mg ml 200 mg-40 mg 5 ml 2% napsylate 325 mg-100 mg Vitamin B Complex Vitamin B Complex Vitamin B Complex Vitamin B Complex Vitamin B Complex Balanced Salt Solution 200 mg-200 mg-20 mg 5 ml 2.5% 200 mg-200 mg-25 mg 35 mcg-0.4 mg Route intramuscular compounding topical ophthalmic topical ophthalmic ophthalmic topical topical ophthalmic oral compounding oral oral oral topical injectable injectable injectable oral injectable injectable oral injectable oral oral intravenous oral nasal topical topical topical injectable oral oral oral oral oral oral ophthalmic oral topical topical topical oral oral topical topical Form powder for injection powder ointment ointment ointment ointment ointment ointment ointment ointment tablet powder tablet tablet tablet liquid powder for injection powder for injection powder for injection capsule powder for injection powder for injection capsule solution tablet tablet solution suspension ointment w applicator cream ointment ointment solution tablet tablet tablet tablet tablet tablet solution suspension ointment liquid oil tablet, chewable tablet lotion lotion MMDC 3946 16291 3978! 1. Wilde MI, Balfour JA, Gestodene. Drugs 50: 364-395, 1995. Guillebaud J, Oral Contraceptive Compliance: What You and Your Patients Need to Know. New York: Churchill Livingstone, 1994. 3. Carr BR, Re-evaluation of oral contraceptive classifications. Int J Fertil 42 Suppl 1 ; : 133-144, 1997. 4. Speroff L, DeCherney A, Evaluation of a new generation of oral contraceptives. Obstet Gynecol 81: 1034-1047, 1993. Fotherby K, Caldwell ADS, New progestogens in oral contraception. Contraception 49: 1-32, 1994. Endrikat J, Jaques M-A, Mayerhofer M et al, A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 g ethinylestradiol 75 g gestodene and 20 g ethinylestradiol 150 g desogestrel, with respect to efficacy, cycle control and tolerance. Contraception 52: 229-235, 1995. Fitzgerald C, Feichtinger W, Spona J et al, A comparison of the effects of two monophasic low dose oral contraceptives on the inhibition of ovulation. Adv Contracept 10: 5-18, 1994. Spona J, Elstein M, Feichtinger W et al, Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception 54: 71-77, 1996. Korver T, Goorissen E, Guillebaud J, The combined oral contraceptive pill: What advice should we give when tablets are missed? Br J Obstet Gynaecol 102: 601-607, 1995. Kuhl H, Comparative pharmacology of newer progestogens. Drugs 51: 188-215, 1996. Elger W, Steinbeck H, Schillinger E et al, Endocrine-pharmacological profile of gestodene. Adv Contracept Deliv Syst 2: 182-197, 1986. Spona J, Huber J, Pharmacological and endocrine profiles of gestodene. Int J Fertil 32: 6-14, 1987. Dsterberg B, Beier S, Schneider et al, Pharmacological features of gestodene in laboratory animals and man, in Breckwoldt M, Dsterberg B eds ; , Gestodene, A New Direction in Oral Contraception. Carnforth, Lancs, England: Parthenon Publishing, 1988, pp 13-29. 14. Dsterberg B, Ellman H, mller U et al, A three-year clinical investigation into efficacy, cycle control and tolerability of a new low-dose monophasic oral contraceptive containing gestodene. Gynecol Endocrinol 10: 33-39, 1996. Sullivan H, Furniss H, Spona J et al, Effect of 21-day and 24-day oral contraceptive regimens containing gestodene 60 g ; and ethinyl estradiol 15 g ; on ovarian activity. Fertil Steril 72 1 ; : 115-120, 1999. 16. Insler V, Melmed H, Eichenbrenner I et al, The cervical score: A simple semiquantitative method for monitoring of the menstrual cycle. Int J Gynaecol Obstet 10: 223-228, 1972. Hoogland HJ, Skouby SO, Ultrasound evaluation of ovarian activity under oral contraceptives. Contraception 47: 583-590, 1993. Data on File, Wyeth-Ayerst Research. GMR 27309, Protocol #0612G320-UK. 19. Data on File, Wyeth-Ayerst Research. GMR 27308, Protocol #0612G321-UK. 20. Eyong E, Elstein M, Clinical update on a new progestogen-gestodene. Br J Fam Plann 15: 18-22, 1989. Coenen CMH, Hollanders JMG, Rolland R et al, The effects of a low-dose gestodene-containing oral contraceptive on endometrial histology in healthy women. Eur J Contracept Reprod Health Care 1: 325-329, 1996. Oosterbaan HP, An open-label study of the effects of a 24-day regimen of gestodene 60 g ethinyl estradiol 15 g on endometrial histologic findings in healthy women. Eur J Contracept Reprod Health Care 4: 38, 1999. Ethinyloestradiol, in Dollery C ed ; , Therapeutic Drugs. Edinburgh, Scotland: Churchill Livingstone, 1991, pp E65-E71. 24. Ermer JC, Muzzin S, Lim L et al, Pharmacokinetics of a 24-day regimen of gestodene 60 g ethinyl estradiol 15 g. Presented at the 5th Congress of the European Society of Contraception, Prague, Czech Republic, June 1998. 25. Gestodene Study Group 322, The safety and contraceptive efficacy of a 24-day low-dose OC regimen containing gestodene 60 g and ethinyl estradiol 15 g. Eur J Contracept Reprod Health Care 4: 915, 1999 and voltaren. Mal contraceptive system or a norgestimatecontaining oral contraceptive OC ; with 35 mcg ethinyl estradiol during the study period of April 1, 2002, through December 31, 2004. We then excluded women with insurance claims mentioning malignancy other than nonmelanoma skin cancer, coagulation defects, long-term anticoagulant use, prior venous thromboembolism, chronic inflammatory diseases, or chronic renal failure. The final study cohort consisted of women who had at least 183 days of continuous enrollment in the health plan. We used the outpatient pharmacy records to identify all dispensings of the transdermal contraceptive system or a norgestimate-containing OC during the study period. We included, for follow-up, periods of "current" and "recent" exposure to the transdermal contraceptive system and norgestimate-containing OCs. Current exposure periods encompassed days from the dispensing date through the number of days of contraception supplied, plus an additional 28 days to allow for gaps in prescription refills. Recent exposure time began after the end date of current exposure and continued through the following 183 days. Each dispensing of the transdermal contraceptive system or a norgestimatecontaining OC reset the exposure window to current. Dispensing of any hormonal contraception other than the transdermal contraceptive system or a norgestimatecontaining OC ended the current or recent exposure period. Norgestimate-containing OC dispensings that occurred before April 2002, with the days supplied extending into April 2002, were also considered in the analysis. We calculated person-time of follow-up for all women beginning on the later of their initial date of the transdermal contraceptive system or other norgestimate-containing OC dispensing, or April 1, 2002. Follow-up continued through the earliest of their date of health plan disenrollment, index date of the outcome, death, or December 31, 2004. The study endpoints were venous thromboembolism, AMI, and ischemic stroke, individually, and the following combined endpoints: 1 ; AMI and ischemic stroke, 2 ; AMI, ischemic stroke, and pulmonary embolism, and 3 ; AMI, ischemic stroke, and venous thromboembolism. We confirmed all cases through medical record abstraction. To identify potential cases, we initially identified all women in the final study cohort with a medical claim inpatient or outpatient ; associated with. Method: A 25-year longitudinal study of a birth cohort of New Zealand children N 982 ; provided the data. DSM-IV symptom criteria for major depression and anxiety disorders, suicidal ideation and attempted suicide, achieving university degree or other tertiary education qualification, welfare dependence and unemployment, and income at ages 21 to 25 years were outcome measures. Results: Associations between the frequency of depression at ages 16 to 21 years and all outcome measures were significant p .05 ; . The association between frequency of depression and all mental health outcomes, and welfare dependence and unemployment, remained significant p .05 ; after adjustment for confounding factors. Conclusions: The rate of depression in adolescence and young adulthood is associated with negative mental health and economic outcomes in early adulthood. Table 6: Drugs Which May Decrease the Efficacy of Oral Contraceptives Class of Drug Proposed Mechanism Suggested Management Compound Use higher dose oral Induction of hepatic Anticonvulsants Carbamazepine contraceptives 50 g microsomal enzymes. Rapid Ethosuximide ethinyl estradiol ; , another metabolism of estrogen and Phenobarbital drug or another method. increased binding of progestin Phenytoin and ethinyl estradiol to SHBG. Primidone Lamotrigine Antibiotics Ampicillin Enterohepatic circulation For short course, use Cotrimoxazole disturbance, intestinal hurry. additional method or use Penicillin another drug. For long course, use another method. Use another method. Rifampin Increased metabolism of progestin Suspected acceleration of estrogen metabolism. Chloramphenicol Induction of hepatic For short course, use microsomal enzymes. Also Metronidazole additional method or use disturbance of enterohepatic Neomycin another drug. For long circulation. Nitrofurantoin course, use another method. Sulfonamides Tetracyclines Troleandomycin May retard metabolism of oral contraceptives, increasing the risk of cholestatic jaundice. Antifungals Griseofulvin Stimulation of hepatic Use another method. metabolism of contraceptive steroids may occur. Cholesterol Clofibrate Reduces elevated serum Use another method. Lowering Agents triglycerides and cholesterol; this reduces oral contraceptive efficacy. For short course, use Sedatives and Benzodiazepines Induction of hepatic microsomal enzymes. additional method or another Hypnotics Barbiturates drug. For long course, use Chloral hydrate another method or higher Glutethimide dose oral contraceptives. Meprobamate Antacids Decreased intestinal absorption Dose two hours apart. of progestin Reduced oral contraceptive Other Drugs Phenylbutazone efficacy has been reported. Antihistamines Remains to be confirmed. Analgesics Antimigraine preparations Vitamin E. 0.1 mg levonorgestrel 0.02 mg ethinyl estradiol tablets 10. Guo CY, Thomas WEG, El-Dehaimi AW, Assiri AMA, Eastell R 1996 ; Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 81: 3487-3491. 11. Silverberg SJ, Gartenberg F, Jacobs TP, Shane E, Siris E, Staron RB, Bilezikian JP 1995 ; Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism. J Clin Endocrinol Metab 80: 723-728. 12. Rao DS, Wilson RJ, Kleerekoper M, Parfitt 1988 ; Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course. J Clin Endocrinol Metab 67: 1294-1298. 13. Grey AB, Stapleton JP, Evans MC, Reid IR 1996 ; Accelerated bone loss in postmenopausal women with mild primary hyperparathyroidism. Clin Endocrinol 44: 697-702. 14. Gallagher JC, Nordin BEC 1972 ; Treatment with oestrogens of primary hyperparathyroidism in postmenopausal women. Lancet 1: 503-507. 15. Selby PL, Peacock M 1986 ; Eghinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women. N Engl J Med 314: 1481-1485. 16. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Reid IR 1996 ; Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. Ann Intern Med 125: 360-368. 17. Parfitt 1996 ; Hormonal influences on bone remodeling and bone loss: application to the management of primary hyperparathyroidism. Ann Intern Med 125: 413-415. 18. Stefenelli T, Abela C, Frank H, KollerStrametz J, Globits S, Bergler-Klein J, Niederle B 1997 ; Cardiac abnormalities in patients with primary hyperparathyroidism: implications for follow-up. J Clin Endocrinol Metab 82: 106-112. 19. Coen G, Bondatti F, de Matteis A, Ballanti P, Mazzaferro S, Sardella D, Smacchi A 1989 ; Severe vitamin D deficiency in a case of primary hyperparathyroidism caused by parathyroid lipoadenoma, effect of 25OHD3 treatment. Miner Electrolyte Metab 15: 332337. 20. Patron P, Gardin JP, Borensztein P, Prigent A, Paillard M 1989 ; Market direct suppression of primary hyperparathyroidism with osteitis fibrosa cystica by intravenous administration of 1, 25-dihydroxycholecalciferol Miner Electrolyte Metab 15: 321-325. SPECIAL SECTION: ALCOHOLISM TREATMENT based treatments e.g., Humphreys, Huebsch, Finney, & Moos, 1999; Morgenstern, Labouvie, McCrady, Kahler, & Frey, 1997 ; or with treatments not explicitly based in 12-step philosophy e.g., McCrady, Epstein, & Hirsch, 1996 ; . In this capacity, AA has been found to be associated with improved outcomes among persons with AUD. Twelve-step-based treatments. Twelve-step-based treatments are modeled on the basic principles of AA and are facilitated by treatment professionals. Among the most prominent of these treatments is the so-called Minnesota model. This model is an abstinence-oriented, spiritually focused approach that works in conjunction with AA and commonly includes psychoeducation, medication, and psychotherapy Cook, 1988; Sheehan & Owen, 1999 ; . Although some positive outcomes for Minnesota model treatment have been reported see Stinchfield & Owen, 1998 ; , there is an absence of controlled research supporting this approach's efficacy. Other 12-step-based interventions have evolved out of clinical trials. Because of their similar structure, such interventions allow for the evaluation of some aspects of AA but are distinct from actual A A participation PMRG, 1997a ; . A few studies of TSF have been conducted, and there has been evidence to support its efficacy. For example, in the first randomized clinical trial comparing TSF with other empirically based treatment modalities cognitive behavioral coping skills and MET ; , PMRG 1997a ; found improvement on drinking measures across all three treatments. TSF performed equally well to the other two treatments, and even demonstrated better outcomes among participants without comorbid psychopathology PMRG, 1997a ; . Further, both the PMRG study and a study by Moos, Finney, Ouimette, and Suchinsky 1999 ; found persons in TSF to report higher rates of continuous abstinence than persons in CBT. As in Project MATCH, significant outcome improvements were found across treatment groups in the Moos et al. study. Although the Moos et al. study was not a randomized clinical trial, results support the Project MATCH findings regarding the efficacy of 12-step interventions and suggest the generalizability of these findings to clinical populations and buy estradiol. 17-Estradiol Norethindrone Acetate CombiPatch 17-Estradiol Norgestimate Ortho-Prefest ; Conjugated Estrogens CE ; Medroxyprogesterone Acetate MPA ; Premphase ; Conjugated Estrogens Medroxyprogesterone Acetate Prempro ; Eth8nyl Estradiol Norethindrone Acetate Femhrt ; Committee Recommendations for the NPDL are: 17-Estradiol Levonorgestrel Climara Pro ; 4-1; 6. Calcium Channel Blockers Dr. Weather offered the motion to accept Provider Synergies' recommendations. The motion was seconded by Dr. Kudla. Discussion followed. Dr. Tilton and Dr. Kinchen indicated Norvasc should be on the PDL and inquired if Provider Synergies could return to Pfizer, attempt to negotiate a rebate and present this class again at the Committee's August, 2005 meeting. Dr. Batie offered the motion to accept Provider Synergies recommendations and request they return to negotiate with Pfizer. Dr. Weather seconded the motion. Dr. Valerie Taylor, Provider Synergies, explained it is not possible to go back under the TOP$ program. Dr. Weather wanted the Committee to consider what other states are doing. Dr. Pope called for information on the cost of a PA, and Dr. Evans wanted to know how many prescriptions had been dispensed for Norvasc over the last three months. Dr. Batie's substitute motion failed and the Committee's original motion carried unanimously. Committee Recommendations for the PDL are: Diltiazem ER Diltiazem IR Diltiazem LA Cardizem LA ; Diltiazem SA Felodipine ER Isradipine SR Dynacirc CR ; Nicardipine Nifedipine ER Nifedipine IR Nisoldipine Sular ; Verapamil ER Verelan ; Verapamil IR Verapamil SA Committee Recommendations for the NPDL are: Amlodipine Norvasc ; Isradipine Dynacirc ; Nicardipine SR Cardene SR ; Nimodipine Nimotop ; Verapamil ER Covera HS ; Drug no longer on Market Bepridil Vascor ; - previously on NPDL 4-1; 7. Beta Blockers Mr. McKay offered the motion to accept Provider Synergies' recommendations. The motion seconded by Dr. Evans carried. Drs. Kinchen and Jastram voted against the motion as they felt Coreg should remain on the PDL. What is ethinyl estradiol and norethindrone Ethinyl estradiol norethindrone acetate Ethonyl, efhinyl, 3thinyl, etbinyl, erhinyl, ethihyl, e6hinyl, ethinly, etthinyl, dthinyl, rthinyl, eth9nyl, ethinyll, ethinyk, ethniyl, e5hinyl, ethiyl, 4thinyl, etyinyl, ethinul, thinyl, etjinyl, ehhinyl, ethijyl, tehinyl, ethibyl, wthinyl, etuinyl, eethinyl, ethiny. Norethindrone ethinyl estrad, ethinyl estradiol fertility, side effects of levonorgestrel and ethinyl estradiol tablets, 0.1 mg levonorgestrel 0.02 mg ethinyl estradiol tablets and what is ethinyl estradiol and norethindrone. Ethinyl estradiol norethindrone acetate, drospirenone ethinyl estradiol 3mg, buy cheap ethinyl and information on levonorgestrel and ethinyl estradiol tablets or estrostep fe ethinyl estradiol norethindrone acetate. Drospirenone ethinyl estradiol 3mg Cretinism nutrient deficiency, asthma products, alveolitis exposure, actinomycetes website and cytokine support. Use abstemious in a sentence, contraction 4 grade, drug encyclopedia and anion vacancy or symptomatic bradycardia treatment. Copyright © 2008 by Cheap-online.50webs.com Inc.